Showing results (201-210 of 241) with videos related to

Sort By:
Pageof 25
Leukemia & Lymphoma|October 27, 2006
Successful mobilization of Ph-negative blood stem cells with intensive chemotherapy + G-CSF in patients with chronic myelogenous leukemia in first chronic phaseUlla Olsson-Strömberg, Martin Höglund, Magnus Björkholm, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 12, 2015
Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemiaHelena Ågerstam, Christine Karlsson, Nils Hansen, et al.
British Journal of Haematology|March 30, 2021
Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registryHjalmar Flygt, Fredrik Sandin, Torsten Dahlén, et al.
Plos One|November 17, 2011
Dissociation of bone resorption and bone formation in adult mice with a non-functional V-ATPase in osteoclasts leads to increased bone strengthKim Henriksen, Carmen Flores, Jesper S Thomsen, et al.
The New England Journal of Medicine|March 15, 2003
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemiaStephen G O'Brien, François Guilhot, Richard A Larson, et al.
American Journal of Hematology|November 23, 2023
Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromesAndrew M Brunner, Jordi Esteve, Kimmo Porkka, et al.
Acta Haematologica|May 5, 2005
Intensive treatment and stem cell transplantation in chronic myelogenous leukemia: long-term follow-upBengt Simonsson, Gunnar Oberg, Mats Bjoreman, et al.
Blood|December 12, 2022
Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemiaHeikki Kuusanmäki, Olli Dufva, Markus Vähä-Koskela, et al.
The New England Journal of Medicine|December 28, 2020
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First RemissionAndrew H Wei, Hartmut Döhner, Christopher Pocock, et al.
Frontiers in Oncology|October 27, 2022
Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysisJesse M Tettero, Waleed K W Al-Badri, Lok Lam Ngai, et al.
Pageof 25